TRXBTRex Bio, Inc.

US ExchangeHealth Care2026-10-09

Clinical-stage biopharma developing immunoregulatory medicines, including TNFR2 agonist TRB-061, to restore immune balance in autoimmune/inflammatory diseases.

$14IPO price

$116MRaised

$14Day-1 close

0.00%Day-1 return

Clinical-stage biopharma developing immunoregulatory medicines, including TNFR2 agonist TRB-061, to restore immune balance in autoimmune/inflammatory diseases.

Company description (source: StockAnalysis)

TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company’s product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balanc...

生物医药临床阶段自身免疫

51CFO read: Requires CFO skilled in immuno-oncology/immunology pipeline valuation, clinical-data-driven investor narrative, and autoimmune-focused capit

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us